VEDANTA BIOSCIENCES INC.

Products

Category

Product

Brand

Description

Human Microbiome-based Drugs and Diagnostics (BIO151B)

VE202		An orally administered bacterial consortium drug candidate consisting of 16 strains of live commensal bacteria. It is designed to treat various imbalance issues in IBD, such as gut dysbiosis, and restore intestinal homeostasis. The drug candidate can induce markers in the gut to maintain the integrity of the gut barrier.
VE303		An orally administered product of a defined bacterial consortium with eight strains of live commensal bacteria. It is intended for the treatment of C. difficile infection. The company is conducting a phase 3 RESTORATiVE303 study to evaluate the drug to prevent recurrent CDI. The product received fast-track designation by the U.S. FDA, and the trial is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).
VE707		A preclinical candidate for the prevention of gram-negative infections. The drug can potentially treat gram-negative antimicrobial-resistant infections in oncology, urology, transplantation, and critical care patients. The company received $16.6 million from CARB-X for the development of the VE707.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment